10 clinical sites selected to participate in the FDA Phase 2 clinical study evaluating ketamine for the treatment of Parkinson’s Disease Initiated investigational new drug (IND) application to proceed to a Phase 2 clinical study for KETABET to treat depression Completed Phase 2 clinical study protocol for ketamine to treat ALS for IND submission to the FDA Near completion of research programs to…


Previous articleThe Therapeutic Effects of Psychedelics: 2A or Not 2A? – Part 1
Next articlePerception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression